Chardan’s 5^th Annual Genetic Medicines Conference on October 5 at 1:30 pm ET

President, Founder and Chief Executive Officer to participate in the “What’s Next for Advanced Therapies” panel at Meeting on the Mesa on October 12, 2021 at 7:15 am PT

Chief Medical Officer and Head of R&D to deliver corporate presentation at Meeting on the Mesa on October 12, 2021 at 2:30 pm PT

Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in a fireside chat at Chardan’s 5^th Annual Genetic Medicines Conference and a panel discussion and corporate presentation at the Cell & Gene Meeting on the Mesa on October 12, 2021. Meeting on the Mesa is the largest annual partnering meeting dedicated solely to the cell and gene therapy sector, attracting more than 1,200 attendees through the three-day program and featuring presentations and talks by major companies in the space.

The “What’s Next for Advanced Therapies” panel will feature leading executives in the advanced therapies medicinal product (ATMP) space who will discuss a number of topics including recent advancements in clinical trials, going from treating rare diseases to prevalent conditions and implementing next-generation gene-editing technologies. The session will also touch upon resolving manufacturing and talent bottlenecks as the sector moves towards commercialization, as well as the evolution of reimbursement payment models.

A webcast for the Chardan conference will be available in the “Events & Media” section of the Taysha corporate website at https://ir.tayshagtx.com/news-events/events-presentations. Archived versions of the webcast will be available on the website for 60 days.

About Taysha Gene Therapies

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210928006083/en/